Biomarkers May Help Predict Remission Among Patients With Severe Asthma After Anti-IL-5 Therapy, Study Finds

Healio (12/11, Hornick) reports, “Sputum neutrophil percentage and levels of eotaxin-1, IL-5 and eosinophil peroxidase may be used to predict remission among patients with severe asthma 1 year after anti-IL-5 therapy, according to a study.” Researchers found “sputum type 2 markers levels could be surrogate markers of response 1 year after anti-IL-5 treatment.” The findings were published in CHEST.